Study to Evaluate the Safety and Efficacy of Everolimus, in Subjects With PIK3CA Amplification, PTEN Loss and PIK3CA Mutation Refractory Solid Tumors
PHASE2CompletedINTERVENTIONAL
Enrollment
10
Participants
Timeline
Start Date
February 28, 2015
Primary Completion Date
April 30, 2016
Study Completion Date
August 31, 2016
Conditions
Solid Tumor
Interventions
DRUG
everolimus
everolimus 10 mg qd daily one cycle is 28days.
Trial Locations (1)
135-710
Samsung Medical center, Seoul
All Listed Sponsors
lead
Samsung Medical Center
OTHER
NCT02449538 - Study to Evaluate the Safety and Efficacy of Everolimus, in Subjects With PIK3CA Amplification, PTEN Loss and PIK3CA Mutation Refractory Solid Tumors | Biotech Hunter | Biotech Hunter